​

Monte Rosa Therapeutics (GLUE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

GLUE Stock Forecast

Monte Rosa Therapeutics (GLUE) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $24.83, with a high of $28.00 and a low of $19.00. This represents a 132.93% increase from the last price of $10.66.

$10 $14 $18 $22 $26 $30 High: $28 Avg: $24.83 Low: $19 Last Closed Price: $10.66

GLUE Stock Rating

Monte Rosa Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (80.00%), 2 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 2 8 Strong Sell Sell Hold Buy Strong Buy

GLUE Price Target Upside V Benchmarks

TypeNameUpside
StockMonte Rosa Therapeutics132.93%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3613
Avg Price Target$23.00$24.83$28.69
Last Closing Price$10.66$10.66$10.66
Upside/Downside115.76%132.93%169.14%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2627---9
Sep, 2626---8
Aug, 2626---8
Jul, 2626---8
Jun, 2626---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 11, 2026UBS$19.00$10.3084.47%78.24%
Oct 05, 2026Raymond James$25.00$10.50138.10%134.52%
Oct 01, 2026H.C. Wainwright$25.00$11.93109.56%134.52%
Aug 07, 2026Guggenheim$28.00$15.7178.23%162.66%
Aug 03, 2026Robert DriscollWedbush$27.00$16.1766.98%153.28%
Jul 31, 2026Jefferies$25.00$16.5251.33%134.52%
Jul 27, 2026Jefferies$40.00$22.7875.59%275.23%
Jun 30, 2026Guggenheim$35.00$23.9046.44%228.33%
Jan 14, 2026Piper Sandler$37.00$23.9954.23%247.09%
Jan 07, 2026Jefferies$31.00$23.2933.10%190.81%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 12, 2026UBSBuyBuyhold
Oct 05, 2026H.C. WainwrightBuyBuyhold
Oct 01, 2026H.C. WainwrightBuyinitialise
Aug 03, 2026WedbushOutperformOutperformhold
Jul 27, 2026JefferiesBuyBuyhold
Jun 30, 2026GuggenheimBuyBuyhold
Jan 14, 2026Piper SandlerOverweightOverweighthold
Jan 07, 2026JefferiesBuyBuyhold
Jan 07, 2026Cowen & Co.BuyBuyhold
Jan 07, 2026WedbushOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.63$-0.98----
Avg Forecast$-2.40$-1.01$-1.55$-1.95$-1.87$-0.51
High Forecast$-2.09$-0.97$-0.96$-0.98$-0.31$-0.11
Low Forecast$-2.55$-1.07$-2.05$-3.67$-3.57$-0.87
Surprise %9.58%-2.97%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$75.62M$123.67M---
Avg Forecast$3.53M$66.18M$24.18M$25.96M$86.61M$253.19M
High Forecast$5.49M$82.03M$37.66M$26.74M$134.90M$394.36M
Low Forecast$1.41M$47.62M$9.68M$25.18M$34.68M$101.38M
Surprise %-14.26%411.44%---

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-135.35M$-72.70M$-38.63M---
Avg Forecast$-119.20M$-52.24M$-77.46M$-179.28M$-99.78M$-26.04M
High Forecast$-107.23M$-49.64M$-49.57M$-50.50M$-16.17M$-5.74M
Low Forecast$-131.17M$-54.84M$-105.34M$-188.47M$-183.39M$-44.92M
Surprise %13.55%39.17%-50.13%---

GLUE Forecast FAQ

Is Monte Rosa Therapeutics stock a buy?

Monte Rosa Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Monte Rosa Therapeutics is a favorable investment for most analysts.

What is Monte Rosa Therapeutics's price target?

Monte Rosa Therapeutics's price target, set by 10 Wall Street analysts, averages $24.83 over the next 12 months. The price target range spans from $19 at the low end to $28 at the high end, suggesting a potential 132.93% change from the previous closing price of $10.66.

How does Monte Rosa Therapeutics stock forecast compare to its benchmarks?

Monte Rosa Therapeutics's stock forecast shows a 132.93% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Monte Rosa Therapeutics over the past three months?

  • October 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Monte Rosa Therapeutics’s EPS forecast?

Monte Rosa Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.95, marking a 0% decrease from the reported $0 in 2025. Estimates for the following years are $-1.87 in 2027, and $-0.51 in 2028.

What is Monte Rosa Therapeutics’s revenue forecast?

Monte Rosa Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $25.96M, reflecting a -79.01% decrease from the reported $123.67M in 2025. The forecast for 2027 is $86.61M, and $253.19M for 2028.

What is Monte Rosa Therapeutics’s net income forecast?

Monte Rosa Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-179M, representing an 364.14% increase from the reported $-38.626M in 2025. Projections indicate $-99.779M in 2027, and $-26.041M in 2028.